Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs BAT in High-risk PV or ET (Ruxo-BEAT)
NCT02577926Phase 2Active, not recruiting
- Sponsor
- RWTH Aachen University
- Start
- Oct 2015
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in polycythemia vera (PV), essential thrombocythemia (ET), sponsored by RWTH Aachen University. Started Oct 2015; status: active, not recruiting.
02
Drugs
03
Conditions
polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT02577926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02577926.